AKARI INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Akari Therapeutics, Plc To Contact The Firm

NEW YORK, May 12, 2017 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at Akari Therapeutics, Plc ("Akari" or the "Company") (NASDAQ: AKTX).

The investigation focuses on whether the Company and its executives violated federal securities laws.  Specifically, on May 11, 2017, Akari filed a Form 6-K with the Securities and Exchange Commission announcing that Akari has established an ad hoc special committee to review the involvement of Company personnel regarding a report issued on April 26, 2017 by Edison Investment Research Inc., an investment research and advisory company. Furthermore, the Form 6-K disclosed that Dr. Gur Roshwalb, the Company's Chief Executive Officer, has been placed on administrative leave while the review is pending.

As a result, the price of Akari's American Depositary Receipts ("ADRs") declined significantly, causing harm to investors.

If you invested in Akari ADRs and would like to discuss your legal rights, click here: www.faruqilaw.com/AKTX. There is no cost or obligation to you.

You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to [email protected]. 

CONTACT:
FARUQI & FARUQI, LLP
685 Third Avenue, 26^th Floor
New York, NY 10017
Attn:  Richard Gonnello, Esq.
[email protected]
Telephone: (877) 247-4292 or (212) 983-9330

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter.  We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

SOURCE Faruqi & Faruqi, LLP

Related Links

http://www.faruqilaw.com